The European Medicines Agency’s (EMA) human medicines committee endorsed nine new drugs during its monthly meeting held from May 16 to 19, including LFB Biotechnologies’ coagulant therapy Cevenfacta (eptacog beta (activated)) for treating congenital hemophilia.
Source: Drug Industry Daily